Nature Communications· 2026Q1
Antisense oligonucleotides targeting transcription termination windows disrupt mRNA 3’ end processing and decrease gene expression
- 2citations
- Q1SCImago
- 2026year
Short summary
Antisense oligonucleotides (ASOs) targeting transcription termination windows downstream of protein-coding genes decrease mRNA levels by inducing RNase H1-dependent cleavage, impairing 3' end processing and promoting degradation.
AI-generated from the title and abstract; the full text is not read.
Key points
- Transcription termination windows downstream of genes are identified as novel targets for antisense oligonucleotides (ASOs).
- ASOs in these regions induce RNase H1-dependent cleavage of nascent RNA.
- This cleavage impairs mRNA 3' end processing and promotes exosome-dependent degradation.
- The mechanism also facilitates early entry of XRN2 exonuclease, further suppressing gene expression.
- This approach reveals a potential source of off-target effects for ASOs.
AI-generated from the title and abstract; the full text is not read.
Abstract
ABSTRACT Antisense oligonucleotides (ASOs) are short, synthetic nucleic acids that bind to complementary RNA sequences and alter gene expression, making them versatile therapeutic agents. Here, we identify transcription termination windows of protein-coding genes as previously unrecognized targets for ASOs. We show that ASOs can act on nascent RNA synthesised downstream of the annotated genes, leading to a pronounced decrease in the corresponding mRNA levels. These downstream-of-gene ASOs (DG-ASOs) induce RNase H1-dependent cleavage, impairing mRNA 3’ end processing, directing the unprocessed mRNAs for exosome-dependent degradation and creating early entry points in the nascent RNA for the XRN2 exonuclease termination factor. Altogether, we show that termination windows are genuine ASO targets which can be exploited to suppress gene expression. Importantly, we also reveal an underappreciated source of off-target effects which may arise from ASOs binding downstream of genes. Our findings indicate the necessity to expand ASO design and off-target assessment guidelines to include termination window sequences, thereby improving therapeutic efficacy and safety.
The authors' abstract, as published at the source. Nature Communications, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Molecular Biology
Molecular BiologyBiochemistry, Genetics and Molecular Biology